NVDA
NVIDIA
-- 139.670 TSLA
Tesla
-- 430.600 PLTR
Palantir
-- 80.690 AMD
Advanced Micro Devices
-- 124.600 RGTI
Rigetti Computing
-- 10.9600 
NEWS
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
Viridian Therapeutics (NASDAQ: VRDN) announced positive topline results from the THRIVE Phase 3 clinical trial of veligrotug (VRDN-001) in patients with active thyroid eye disease (TED). The trial met all primary and secondary endpoints, showing significant improvements in proptosis, diplopia, and clinical activity score. Key highlights include:
- 70% proptosis responder rate (64% placebo-adjusted, p < 0.0001)
- 54% complete resolution of diplopia (43% placebo-adjusted, p < 0.0001)
- 64% reduction of Clinical Activity Score to 0 or 1 (46% placebo-adjusted, p < 0.0001)
- Generally well-tolerated with no treatment-related serious adverse events
The company plans to submit a Biologics License Application (BLA) for veligrotug in the second half of 2025. Additionally, Viridian initiated Phase 3 trials for VRDN-003, a subcutaneous anti-IGF-1R antibody, with topline data expected in the first half of 2026.
- 70% proptosis responder rate (64% placebo-adjusted, p < 0.0001)
- 54% complete resolution of diplopia (43% placebo-adjusted, p < 0.0001)
- 64% reduction of Clinical Activity Score to 0 or 1 (46% placebo-adjusted, p < 0.0001)
- Generally well-tolerated with no treatment-related serious adverse events
The company plans to submit a Biologics License Application (BLA) for veligrotug in the second half of 2025. Additionally, Viridian initiated Phase 3 trials for VRDN-003, a subcutaneous anti-IGF-1R antibody, with topline data expected in the first half of 2026.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment